Two different treatment regimens of ranibizumab 0.5 mg for neovascular age‐related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study-Reference-Cited by-同舟云学术

Two different treatment regimens of ranibizumab 0.5 mg for neovascular age‐related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study

Published:2020-12-30 Issue:3 Volume:99 Page:
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmol

Author:

Li Xiaoxin¹^ORCID,Zhu Qi²,Egger Anna³,Chang Liu²,Wolf Sebastian⁴,Song Yanping⁵^ORCID,Zhang Junjun⁶,Dong Fangtian⁷,Xu Xun⁸,Weisberger Annemarie⁹

Affiliation:

1. Peking University People's Hospital Beijing China

2. China Novartis Institutes for Biomedical Research Co., Ltd. Shanghai China

3. Novartis Pharma AG Basel Switzerland

4. Department Ophthalmology, Inselspital Bern University Hospital University of Bern Bern Switzerland

5. Wuhan General Hospital of Guangzhou Military Command Wuhan China

6. West China Hospital Sichuan University Chengdu China

7. Peking Union Medical College Hospital Beijing China

8. Shanghai First People's Hospital Shanghai China

9. Novartis Pharmaceutical Corporation East Hanover New Jersey USA

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.14588

Reference39 articles.

1. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

2. Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

3. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

4. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

5. Profile of ranibizumab: efficacy and safety for the treatment of wet age‐related macular degeneration;Chen Y;Ther Clin Risk Manag,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 91 Circulating inflammatory proteins and the risk of age-related macular degeneration: A bidirectional Mendelian randomization study;International Immunopharmacology;2024-09

2. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis;BMJ Open Ophthalmology;2024-07

3. Pro re nata anti-VEGF treatment in pachychoroid neovasculopathy compared with age-related macular degeneration based on optical coherence tomography;International Ophthalmology;2024-03-29

4. Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial;Current Eye Research;2024-03-07

5. Research Progress on the Etiology of Polypoid Choroidal Vascular Disease;Advances in Clinical Medicine;2024